However, in the last years significant advancements have been achieved mostly thanks to the new methodologies available to explore the cancer genome, such as next generation sequencing (NGS), which has allowed the recognition of the myeloid differentiation factor 88 (MYD88) L265P mutation as the most frequent molecular lesion associated to this disease (found in than 90% of cases) (6). Here, MYD88 is linked to cancer.